Repligen (RGEN) announced the launch of AVIPure dsRNA Clear OPUS columns, a solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity ...
WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of AVIPure ® ...
Accelerates expansion into new modality markets with a unique, scalable purification solution Strongly synergistic with AVIPure ® affinity ligands and OPUS ® pre-packed chromatography columns WALTHAM, ...
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications Accelerates expansion into new modality markets with a unique, scalable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results